Open House Original Discount Agreements 2025-10 - Umeclidinium Bromide + Vilanterol
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-10 - Umeclidiniumbromid+Vilanterol
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed minimum volume or estimated value; actual uptake may be low.
Contract terminates automatically upon patent expiry of the drug combination.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Conclusion of discount agreements for the drug combination Umeclidiniumbromid+Vilanterol under §130c SGB V.
- Open House procedure: uniform conditions, no individual negotiations.
Show full summary
Open House procedure by Techniker Krankenkasse for discount agreements on the drug combination Umeclidiniumbromid+Vilanterol (CPV 33600000). Contract period max 24 months from 01.05.2025 to 30.04.2027. No exclusivity; any eligible pharmaceutical entrepreneur can join at any time.
Risks
No guaranteed minimum volume or estimated value; actual uptake may be low.
Contract terminates automatically upon patent expiry of the drug combination.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
- Must have valid marketing authorization for the specific drug combination.
Eligibility
- Must submit declaration of eligibility (Anlage 4) with signed documents.
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Original Discount Agreements 2025-10 - Umeclidinium Bromide + Vilanterol
Discount agreement for the drug combination Umeclidinium bromide + Vilanterol.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Umeclidiniumbromid+Vilanterol zu schließen.
Show original TED data
Original lot title
Open House Originale Rabattverträge 2025-10 - Umeclidiniumbromid+Vilanterol
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Umeclidiniumbromid+Vilanterol zu schließen.
Procurement Details
- Publication date
- 27 Mar 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 201823-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed minimum volume or estimated value; actual uptake may be low.
Contract terminates automatically upon patent expiry of the drug combination.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications